With the conclusion of another ASCO, we were presented with exciting new breakthrough data of Antibody Drug Conjugates in breast cancer. Enhertu (trastuzumab deruxtecan) demonstrated significant benefit in the treatment of a new subtype of breast cancer, HR+/ /HER2-low.
As ASCO concludes for another year, here at Deallus we were excited to see significant data announcements by Chinese innovators, unveiling enormous potential from China-originated innovation to address unmet needs within the oncology space.
We’re excited to be attending The BIO International Convention. Jack Florio, Partner in Strategy Consulting at Deallus will be joining more than 3,000 delegates and exploring the latest innovation within the biotech space, as well as making the most of opportunities to meet and network with global thought leaders and industry peers.
China is never a new word in ASCO. China-originated innovation made its ASCO debut in 2011, and since then we have been seeing more Chinese pharma bringing exciting clinical progress in the oncology space. This year, there will be 19 oral presentations and more than 70 posters from Chinese pharma, with the keyword 'China’ hit a record high of nearly 350 times in the ASCO Agenda.
Deallus is delighted to announce that George Gu joined our team on the 6th of April. Medical Doctor by training - focusing on Radiation Oncology - George has spent the last 7 years working with various consulting and start-up companies, gaining valuable experience in medical internet and genomic profiling companies.
We are very pleased to welcome Kevin Bibby to our Deallus team as Senior Principal. Kevin brings extensive expertise in commercial strategy to the fold, as well as a deep background in brand and portfolio strategy, product positioning, and workshop facilitation. We look forward to adding his knowledge, skill sets, and collaborative spirit to the team.
